" /> Enavatuzumab - CISMeF





Preferred Label : Enavatuzumab;

NCIt synonyms : Anti-tumor Necrosis Factor-like Weak Inducer of Apoptosis Monoclonal Antibody PDL192; Anti-TWEAKR Monoclonal Antibody PDL192;

NCIt definition : A humanized monoclonal antibody directed against the tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) with potential antineoplastic, immunomodulating and antiangiogenic activities. Enavatuzumab binds to TWEAKR and inhibits TWEAK ligand binding and activation of NF-kappaB-mediated cytokine release, which may result in tumor cell apoptosis. TWEAKR is a cell-surface receptor with homology to tumor necrosis factor receptors. Upon binding with its ligand, TWEAKR has been shown to stimulate cytokine release and cell proliferation, migration, and survival; it may also promote apoptosis under some conditions. This receptor may be overexpressed in a variety of tumors including those of the pancreas, colon, lung, kidney, and breast.;

UNII : 914910XFBB;

CAS number : 1062149-33-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1062149-33-0 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : PDL 192;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
16/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.